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http://www.nutritionj.com/content/12/1/138RESEARCH Open AccessHypocaloric diet supplemented with probiotic
cheese improves body mass index and blood
pressure indices of obese hypertensive patients - a
randomized double-blind placebo-controlled pilot
study
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Background: Gut lactobacilli can affect the metabolic functions of healthy humans. We tested whether a 1500
kcal/d diet supplemented with cheese containing the probiotic Lactobacillus plantarum TENSIA (Deutsche
Sammlung für Mikroorganismen, DSM 21380) could reduce some symptoms of metabolic syndrome in Russian
adults with obesity and hypertension.
Methods: In this 3-week, randomized, double-blind, placebo-controlled, parallel pilot study, 25 subjects ingested
probiotic cheese and 15 ingested control cheese. Fifty grams of each cheese provided 175 kcal of energy. Blood
pressure (BP), anthropometric characteristics, markers of liver and kidney function, metabolic indices (plasma
glucose, lipids, and cholesterol), and urine polyamines were measured. Counts of fecal lactobacilli and L. plantarum
TENSIA were evaluated using molecular methods. The data were analyzed by t-test for independent samples and
Spearman’s partial correlation analysis.
Results: The probiotic L. plantarum TENSIA was present in variable amounts (529.6 ± 232.5 gene copies) in 16/25
(64%) study subjects. Body mass index (BMI) was significantly reduced (p = 0.031) in the probiotic cheese group
versus the control cheese group. The changes in BMI were closely associated with the water content of the body
(r = 0.570, p = 0.0007) when adjusted for sex and age. Higher values of intestinal lactobacilli after probiotic cheese
consumption were associated with higher BMI (r = 0.383, p = 0.0305) and urinary putrescine content (r = 0.475,
p = 0.006). In patients simultaneously treated with BP-lowering drugs, similar reductions of BP were observed in
both groups. A positive association was detected between TENSIA colonization and the extent of change of
morning diastolic BP (r = 0.617, p = 0.0248) and a trend toward lower values of morning systolic BP (r = −0.527,
p = 0.0640) at the end of the study after adjusting for BMI, age, and sex.
Conclusion: In a pilot study of obese hypertensive patients, a hypocaloric diet supplemented with a probiotic
cheese helps to reduce BMI and arterial BP values, recognized symptoms of metabolic syndrome.
Trial registration: Current Controlled Trials ISRCTN76271778
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Obesity, obesity-related disorders, and metabolic syn-
drome have become an epidemic in Western societies.
Obesity results from complex interactions between genes
and environmental factors such as diet, food components,
and lifestyle. Metabolic syndrome consists of a group of
factors involved in an increased risk of developing cardio-
vascular diseases and type 2 diabetes. Three or more of
the following signs define metabolic syndrome: obesity
and insulin resistance, increased blood pressure (BP), high
fasting blood triglycerides and glucose, and low high-
density lipoprotein levels [1,2]. Alvarez-Leon et al. [3] have
pointed on the inverse association between ingestion of
dairy products and high BP. Low-fat spreads containing
bioactive milk peptides were able to reduce systolic blood
pressure (SBP) and serum cholesterol in hypertensive and
hyper-cholesterolemic subjects [4]. However, the beneficial
influence of dairy products on BP and cardiovascular
health has not been assessed regarding cheese or other
traditionally high-fat products [5].
Interactions between intestinal microbiota and host play
an important role in the physiological regulation of meta-
bolic functions and the development of various diseases.
Different health-improving effects of various Lactobacillus
spp. have been demonstrated after their application as nat-
ural or designer probiotics [6,7]. Probiotics are defined as
live microorganisms that confer a health benefit to the
host when administered in adequate amounts [8]. Pro-
biotic Lactobacillus strains possess various functional
properties for health promotion, including high antimicro-
bial activity against pathogens, cholesterol-lowering ef-
fects, antioxidative properties, and immunogenic potential
[9-11]. Lactobacillus helveticus-fermented milk containing
bioactive peptides reduced BP in hypertensive subjects
when ingested daily [12]. However, strain-specific health
effects may be associated with significant differences in
the production of specific metabolites among the Lactoba-
cillus strains [13-16].
Recent assessments of diets combined with probiotics
have been directed towards the control of biomarkers of
the host’s basic metabolism, particularly carbohydrates,
lipids, and amino acid turnover after dairy probiotic ad-
ministration for different hosts [17,18]. However, whether
the addition of a probiotic strain to full-fat dairy products
can improve the functionality indices of the host remains
to be elucidated.
This study evaluates the clinical efficacy of a hypocaloric
diet supplemented with cheese with a moderate fat con-
tent that includes the probiotic Lactobacillus plantarum
TENSIA (Deutsche Sammlung für Mikroorganismen,
DSM 21380) in Russian adult patients with obesity and
hypertension with particular accompanying diseases under
standard treatment. BP, anthropometric characteristics,
markers of liver and kidney function, metabolic indices(plasma glucose, lipids, and cholesterol), and urine poly-
amines were tested. Counts of fecal lactobacilli and intes-




L. plantarum TENSIA was previously isolated from the
gastrointestinal tract of healthy Estonian children [19].
The strain L. plantarum TENSIA® has been deposited in
the Deutsche Sammlung von Mikroorganismen und
Zellkulturen [German Collection of Microorganisms and
Cell Cultures] GmbH under registration number DSM
21380 at 16.04.2008. Molecular identification of the
strain as L. plantarum was confirmed by internally tran-
scribed spacer polymerase chain reaction and 16SrRNA
sequencing [20]. The safety of the strain was confirmed
previously using an animal model [21], as well as in
Estonian healthy adults and elderly subjects (registered
trials ISRCTN38739209 and ISRCTN45791894) [22].
Cheese preparation
The probiotic cheese containing L. plantarum TENSIA
was developed at E-Piim Production in Estonia under
the trademark Harmony™ [22]. Two similar cheeses were
prepared on the basis of regular Edam-type cheese with
a starter C92 (CSK Food Enrichment,Netherlands). To
produce the probiotic cheese, the L. plantarum TENSIA
was added to the cheese milk in amounts of 1.5x1011
CFU/g before renneting. Both cheeses (probiotic and
control) were similarly ripened for 4 weeks at 10-12°C
and 80-85% relative air humidity. The microbial com-
position of test and control cheeses did not differ in the
counts and prevalence of non-starter microbiota. In pro-
biotic cheese the viability of L. plantarum TENSIA was
assessed before the human trial. The energy provided by
consumption of 50 g of each cheese was 175 kcal.
The composition and energy value (1512 kcal) of a
standard hypocaloric diet is depicted in Table 1.
Study population
Participants in the clinical trial were randomly selected
from consecutive patients admitted to the Clinic of the
Institute of Nutrition (Russian Academy of Medical
Sciences) from January 2011 until March 2011. The
number of expected hospitalized patients (approximately
40 patients for 3 months) relevant to inclusion criteria
was postulated. Inclusion criteria for the patients were:
age 30–69 years, a diagnosis of metabolic syndrome
characterized by obesity accompanied by arterial hyper-
tonia (>130/85 mm Hg), the absence of uncompensated
chronic diseases needing intensive treatment, and in-
formed consent for participation and treatment with a
hypocaloric diet supplemented with a probiotic. Exclusion
Table 1 Composition and energy value of a standard
hypocaloric diet
Substrate Value
Energy value, kcal 1512
Protein, g (%) 81 (21.4)
Vegetable protein, g 28.3
Fat, g (%) 52 (31.0)
Vegetable fat, g 23.4
Saturated fatty acids, g (%) 14.4 (8.5)
Monounsaturated fatty acids, g (%) 16.5 (9.7)
Polyunsaturated fatty acids, g (%) 15.3 (9.0)
Cholesterol, mg 231


























Probiotic count in cheese, log CFU/g 8.7
Daily dose of probiotic, logCFU 10.4
Daily dose of cheese, g 50
Fat intake with cheese, g/d 13
Saturated fat intake with cheese, g/d 8
Cholesterol intake with cheese, mg/d 45
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allergy or acute infection, use of any antimicrobial agent
within the preceding month, pregnancy or breast-feeding,
and no wish to participate. The primary outcomes were
defined both as a significant (p < 0.05) decrease of arterial
blood pressure and body mass index (BMI).
All participants provided written informed consent
and were informed that they could withdraw from the
study at any time; however, no withdrawals were regis-
tered during the hospital stay period.
Study participants were randomly allocated according
to SPSS 17 for Windows into two groups.
The 40 patients were randomly divided into treat-
ment and control groups according to the mode: 2 pa-
tients of treatment group vs.1 patient for control group
(Figure 1). The randomized, double-blind, placebo-
controlled, parallel-designed, two-armed intervention
study was performed and conducted according to the
guidelines laid down in the Declaration of Helsinki
1996–2000. The Ethical Committee of the Institute of
Nutrition of AMS of Russia approved the study proto-
col. The trial was completed in accordance with good
clinical practice [registered trial ISRCTN76271778].
The demographic, clinical, and medication data of the
study and control groups are presented in Table 2.
Study protocol
Altogether, the trial lasted for 3 weeks. For the treatment
group, the standard hypocaloric diet was supplemented
with 50 g/day of probiotic product (semi-hard cheese)
containing L. plantarum TENSIA. Members of the con-
trol group consumed the same amount of a probiotic-
free cheese (Table 1). Implementation and allocation
methods were determined by the clinical coordinator
(KS, Clinic of Institute of Nutrition) during the partici-
pants’ stay in the hospital. The technical assistant con-
firmed the consumption of the cheese, and was blinded
to which cheese contained or lacked probiotic. The med-
ical doctors keeping the records were also blinded to
cheese type. The code was kept in sealed envelopes and
opened after all results of clinical and laboratory ana-
lyses had been registered.
Anthropometric markers were measured, and the ef-
fect of the diet supplemented with the probiotic cheese
on patients’ health indices was evaluated. The body
composition, e.g. fat and muscle mass and total body
water content were estimated by bioelectrical impedance
analysis (InBody 720, Korea). BP was measured twice
daily (morning and evening) at the hospital; BP was
measured on the right arm using a sphygmomanometer,
with subjects in sitting position after 5 min rest. After
BP was measured, blood samples were collected at re-
cruitment (day 0) and at the end of the trial (day 21).
Plasma glucose, plasma lipids, cholesterol, and markers









50 g cheese day /3 weeks
Spearman’s partial correlation analyses for  
studied variables Adjusted for study group,  











Student T test /  
Mann-Whitney
Figure 1 Patient dispensation throughout the study and the statistical analysis. Blocked randomization lists were produced by the
statistician (MV) and held centrally. All invited hospitalized patients attended the study and gave written informed consent before inclusion.
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(AST), alanine aminotransferase (ALT), and serum creatin-
ine] were determined with standard laboratory methods
using certified assays in the clinical laboratory of the hos-
pital (Table 3). Intervals for routine laboratory tests pro-
posed by the Nordic Reference Interval Project (NORIP)
were used as references [23].
Urine and fecal samples were collected before and
after completing the trial and sent to Estonia, University
of Tartu, Biomedicum. The urinary creatinine and poly-
amine content was tested. In fecal samples, the survival
of L. plantarum TENSIA and the number of total lacto-
bacilli were estimated.
Detection of polyamines in cheese and urine samples
GC analysis was performed using a Hewlett-Packard HP
model 6890 gas chromatograph (Hewlett Packard, USA)
equipped with a split/splitless capillary inlet system and a
flame ionization detector. The GC column was a 30 m ×
0.32 mm (i.d.) fused silica capillary coated with cross-
linked 5% phenylmethyl silicone (film thickness 0.25 mm).
The detector temperature was 350°C and the injector
temperature was 200°C. The oven temperature pro-
gram was a gradient system: the initial temperature
was 150°C, it increased to 280°C at a rate of 20°C/min,
and it remained at 280°C for 4.5 min. The chromato-
graphic peak areas were integrated with a Hewlett-
Packard networking integrator.Cheese
Ten grams of cheese were weighed, chopped into very
small fragments, and placed in a plastic bottle that
contained 20 mL of a 50% methanol solution (HPLC
grade, Aldrich, USA). The solution was homogenized by
vortex mixing for 5 min. The cheese mix was then incu-
bated at 45°C for 1 h. Next, the extract was cooled to 30°C
and centrifuged at 4000 rpm for 15min [24]. To detect
poly- and biogenic amines, 200 μL of the supernatant
was analyzed using propyl chloroformate (HPLC grade,
Aldrich, USA). Polyamine concentrations in cheese
were expressed in mg/L.Urine
Urine samples (1 mL each) were mixed with 1 mL of
dichloromethane containing 5 μL propyl chloroformate.
After the first mixing, the pH of the mixture was in-
creased to greater than 12 with 5 M sodium hydroxide
solution. The aqueous phase was removed; the organic
phase was centrifuged at 3000 rpm for 5 min, and the
remaining aqueous phase was removed. Subsequently,
the organic phase was concentrated under a stream of ni-
trogen, and 1 μL was injected onto the GC system. The
calibration graphs were prepared using polyamine stand-
ard solutions at different concentrations (3–150 nmol);
1.6-diaminohexane was used as an internal standard. Poly-
amine concentrations in urine were expressed as mmol/
Table 2 Demographic, clinical, and medication data of
patients in probiotic and control groups
Characteristics % Control group
N = 15
Male, n (%) 9 (36%) 4 (27%)
Female, n (%) 16 (64%) 11 (73%)
Age, years 52.0 ± 10.9 51.7 ± 12.1
Body weight, kg 105.6 ± 16.2 102.4 ± 14.4
Body mass index, kg/m2 37.7 ± 4.3 36.3 ± 4.1
Stage I, n 4 3
Stage II, n 12 8
Stage III, n 9 4
Systolic BP, mm Hg 134.0 ± 8.0 131.4 ± 6.6
Stage I, n 2 3
Stage II, n 16 8
Stage III, n 7 4
Diastolic BP, mm Hg 82.4 ± 6.1 82.1 ± 5.8
Drugs used, n (%) 21 (84%) 12 (80%)
Ca antagonist 4 2
Beta-blocker 4 3
ACE inhibitor 12 7
Diuretics 2 1
Others 2 1
Smokers, n (%) 3 2
Data are presented as mean ± standard deviation unless otherwise noted.
Fisher’s exact test and t-test: There were no statistical differences between any
indices in the two patient groups. BMI scale: overweight = BMI of 25–29.9 kg/
m2; grade 2 overweight (commonly called obesity) = BMI of 30–39.9 kg/m2;
grade 3 overweight (commonly called severe or morbid obesity) = BMI ≥40
kg/m2. (NORIP, http://www.furst.no/norip/). Blood pressure (BP) scale: Grade 1
hypertension = systolic blood pressure (SBP) 140–159 and/or diastolic blood
pressure (DBP) 90–99; Grade 2 hypertension = SBP 160–179 and/or DBP
100–109; Grade 3 hypertension = SBP ≥180 and/or DBP ≥110 (28).








Total cholesterol, mmol/L <5.2 5.32 ± 1 25 4.09 ± 1.20 <
LDL, mmol/L < 3.8 3.08 ± 1.11 2.20 ± 0.92
HDL, mmol/L < 1.15 1.13 ± 0.25 0.94 ± 0.17
TG, mmol/L < 1.7 2.80 ± 2.01 2.09 ± 1.62
Serum glucose, mmol/L 3.9 -5.8 7.16 ± 2.84 5.87 ± 1.00
Serum creatinine, μmol/L 50 – 105 80.8 ± 20.0 69.2 ± 19.4
Urea, μmol/L 2.5 – 6.4 4.72 ± 1.21 5.62 ± 2.29
Uric acid, μmol/L 200 – 340 356.1 ± 85.7 393.4 ± 128.6 <
Total bilirubin, μmol/L < 20 14.9 ± 5.68 12.6 ± 4.24
AST, U/L 0 – 35 23.5 ± 8.02 27.8 ± 9.86 <
ALT, U/L 0 – 35 32.8 ± 16.0 36.3 ± 20.9
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density l
LDL, low-density lipoprotein; TG, triglycerides.
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cally using the Jaffe kinetic method [25].
Molecular assessment of total lactobacilli and L.
plantarum TENSIA
DNA extraction
Bacterial DNA from fecal samples was extracted using
the QIA amp DNA stool mini kit (QIAgen, Hilden,
Germany) with some modifications. First, 0.22 g of feces
were re-suspended in 200 μL of TE buffer (10 mM Tris,
10 mM EDTA pH = 8, 20 mg/mL lysozyme, 200 u/mL
mutanolysin) and incubated for 1 h at 37°C. Next, 0.3 g
of 0.1 mm zirconia/ silica beads and 1.4 mL of ASL solu-
tion from the stool mini kit were added to the fecal sam-
ples. The tubes were then agitated for 3 min at 5000
rpm in a mini-bead beater (Biospec Products Inc., USA).
The protocol was then continued as described by the
manufacturer (QIAgen, Germany).
Quantitative analysis by real-time polymerase chain
reaction (RT-PCR)
To establish a quantitative assay, we cloned plasmids
containing the amplified region of target bacteria using
the pGEM-T vector system (Promega, Madison, WI).
The PCR amplicons for L. paracasei and L. plantarum
TENSIA were individually inserted into separate plasmid
vectors; then, the recombinant vectors were transformed
into chemically competent E. coli. Plasmids were puri-
fied by MaxiPrep (Qiagen). The purified plasmids were
quantified by spectrophotometry (QuibitTM, Invitrogen)
of multiple dilutions [26]. Quantification of target DNA
was achieved using serial 10-fold dilutions from 102 to
108 plasmid copies of the previously quantified plasmid
standards. Plasmid standards and samples were run inControl cheese Extent of changes
P Baseline After
treatment
P Probiotic vs. Control
P
0.001 5.34 ± 0.95 4.35 ± 0.87 0.004 0.495
0.004 3.21 ± 0.69 2.64 ± 0.66 0.021 0.276
0.006 1.14 ± 0.26 1.05 ± 0.22 0.229 0.128
0.041 2.14 ± 1.16 1.43 ± 0.56 0.085 0.696
0.171 6.84 ± 1.92 5.64 ± 1.6 0.014 0.875
0.003 70.5 ± 13.6 57.3 ± 7.4 0.007 0.394
0.017 4.66 ± 2.71 3.89 ± 0.98 0.245 0.011
0.07 326.7 ± 147.7 308.8 ± 111.4 0.49 0.252
0.003 14.2 ± 4.83 11.3 ± 3.61 0.005 0.547
0.053 31.5 ± 16.6 25.0 ± 10.5 0.084 0.468
0.390 45.3 ± 36.4 35.9 ± 26.1 0.149 0.118
ipoprotein;
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the bacterial load.
RT-PCR was performed using the ABI PRISM 7500
HT Sequence Detection System (Applied Biosystems,
USA) with optical grade 96-well plates. The PCR reac-
tion to detect total counts of lactobacilli was performed
in a total volume of 25 μL using the SYBR Green PCR
Master mix (PE Applied Biosystems, USA). Each reaction
included 150 ng of template DNA, SYBR Green Mix
(Applied Biosystems, USA), and a final concentration of
2 μM of each primer for total lactobacilli (Lac-F: 3’-
AGCAGTAGGGAATCTTCCA-5’; Lac-R: 3’-CACCGCT
ACACATGGAG-5’)(27). The PCR conditions were as fol-
lows: 2 min at 50°C and 10 min at 95°C; followed by 40
cycles consisting of denaturation at 95°C for 15 s and
annealing-elongation at 60°C for 1 min. To detect L.
plantarum TENSIA, the reaction mixture (25 μL) for
TaqMan assay contained 2×TaqMan Universal PCR
Master Mix (PE Applied Biosystems, USA), 20 pmol of
primers (Tens31: 3’-AACGCAAGCTTTATCCGATG-
5’; Tens32: 3’-GTTAAGGTTTGCAACAGGTC-5’), 10
pmol of TaqMan probe (5’-FAM-ACCCGCGACGTAC
TTAAAAA-Tamra-3’), and 200 ng of extracted DNA.
The thermocycling program was an initial cycleof 95°C
for 10min, followed by 45 cycles of 95°C for 10 s and
60°C for 1 min. The negative controls were both PCR
Master Mixes without DNA. Data analysis was conducted
using Sequence Detection Software version 1.6.3, supplied
by Applied Biosystems, USA.
Statistical evaluation
The trial results were analyzed using SPSS 17 for Win-
dows. Data were presented as mean ± standard devi-
ation or range with median, depending on the normal
or non-parametric distribution of data. The t-test or
Mann–Whitney rank sum test (numerical variables)Table 4 Anthropometric indices and blood pressure values of
Index Probiotic cheese
Baseline After treatment P Bas
Body weight, kg 105.6 ± 16.2 99.9 ± 14.4 <0.001 102.4
BMI, kg/m2 37.7 ± 4.3 35.7 ± 3.8 <0.001 36.3
Waist-to-hip ratio 0.985 ± 0.06 0.984 ± 0.05 0.778 0.993
Muscle mass, kg 33.0 ± 7.7 32.1 ± 7.1 0.677 31.2
Fat mass, kg 46.7 ± 10.3 42.7 ± 9.8 0.169 46.4
Total water content, L 42.6 ± 10.2 41.2 ± 9.7 0.001 41.1
Morning SBP, mmHg 134.0 ± 1.6 121.8 ± 1.5 <0.001 131.
Evening SBP, mmHg 129.4 ± 2.5 120.6 ± 1.2 <0.001 130.
Morning DBP, mmHg 82.4 ± 1.2 78.4 ± 0.9 0.040 82.1
Evening DBP, mmHg 79.6 ± 1.4 78.0 ± 1.2 0.528 79.6
Data are presented as mean ± standard deviation. BMI, body mass index; DBP, dias
SBP, systolic blood pressure.and χ2test or Fisher’s exact test (categorical variables)
were used to determine the between-group differences in
smoking, drugs, and biological sex (Table 2). Differences
from baseline values in treatment and control groups were
evaluated using a paired t-test (normal distribution) or
Mann–Whitney rank sum test (Tables 3, 4 and 5). Differ-
ences in the magnitude (extent) of change among tested
indices (post-treatment values minus baseline values)
between the treatment group and control group were eval-
uated using a t-test or Mann–Whitney test. Spearman’s
partial correlation analysis, controlling the effects of
group, baseline body mass index (BMI), age, and sex on
different tested indices was applied. The correlation ana-
lysis was conducted in the SAS System® (SAS, Cary, NC,
USA) using the CORR procedure (Table 6).
Results
The anthropometric and clinical indices of the two par-
ticipant groups did not differ. The number of patients
taking medical drugs was also similar between the two
groups (84% of the probiotic group vs. 80% of the con-
trol group), and the distribution of drugs did not differ
between the two groups (Table 2). The consumption of
probiotic cheese did not cause any adverse effects aside
from some temporary constipation, which occurred at
similar rates in the two groups. The extents of change
in body weight (−5.7 vs.-4.4 kg, p = 0.083) and BMI
(−2 vs. -1.6 kg/m2, p = 0.031) were larger in the pro-
biotic group than the control group at the end of the
study (Table 4). Concerning the body composition, a
decrease of the total water content (p = 0.001) was
found only in the probiotic group, however, the data of
water, fat and muscle mass and waist-to-hip ratio did
not differ between probiotic and control groups. All
patients treated with BP-lowering drugs registered a
similar significant reduction of both SBP and diastolicpatients after consumption of probioticor control cheese
Control cheese Extent of change
eline After treatment P Probiotic vs. control cheese P
± 14.4 98.0 ± 13.3 <0.001 0.083
± 4.3 34.7 ± 4.2 <0.001 0.031
± 0.06 0.978 ± 0.05 0.590 0.034
± 7.3 30.1 ± 6.6 0.967 0.315
± 7.9 42.4 ± 9.6 0.211 0.180
± 8.8 40.7 ± 7.8 0.072 0.252
4 ± 1.8 120.0 ± 1.8 <0.001 0.978
0 ± 3.3 119.3 ± 1.6 0.004 0.716
± 1.5 78.6 ± 1.0 0.002 0.240
± 1.6 76.4 ± 1.3 0.008 0.026
tolic blood pressure;
Table 5 Urinarypolyamines (mmol/mol of creatinine) in probiotic and control groups





P Probiotic vs. control food
P
Creatinine 14462 ± 8075 12431 ± 6152 0.322 10512 ± 6509 12977 ± 6381 0.967 0.262
Putrescine 0.117 ± 0.07 0.166 ± 0.14 0.207 0.161 ± 0.09 0.110 ± 0.07 0.019 0.014
Acetylated putrescine 0.291 ± 0.33 0.524 ± 1.36 0.410 0.434 ± 0.36 0.192 ± 0.11 0.004 0.036
Tyramine 0.041 ± 0.12 0.0098 ± 0.05 NS 0.074 ± 0.20 0
Acetylatedspermidine 0.220 ± 0.296 0.601 ± 1.85 0.277 0.202 ± 0.12 0.183 ± 0.11 0.115 0.157
Note: 1.3-diaminopropane, cadaverine, histamine, and spermidine were not detected.
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ingested (Table 4).
Although the consumption of full-fat probiotic cheese
reduced the values of total cholesterol, low-density lipo-
protein, high-density lipoprotein, and triglycerides, no
differences in the extents of change were observed
between the probiotic and control groups (Table 3).
Triglycerides (p = 0.041) were reduced only in probiotic
cheese consumers. Although an 18% reduction of blood
glucose level was observed in both groups, statistical
significance was reached only in the control group A
significant increase of urea content was registered in
consumers of probiotic cheese (p = 0.011), although the
urea level remained within the normal range. No differ-
ences in the extents of change in probiotic and control
groups were observed regarding uric acid, total biliru-
bin, AST or ALT levels.
Urinary putrescine and its derivative, acetylated pu-
trescine, exhibited significant change in probiotic versus
control groups, while a significant reduction of these
polyamines was detected in the control group. No
changes were detected in tyramine or acetylated spermi-
dine (Table 5).
The total count of lactobacilli (Figure 2) did not change
after the consumption of probiotic cheese; however, a largeTable 6 Spearman’s partial correlation analysis of probiotic a




Lactobacilli content Putrescine content*
Colonization with TENSIA Morning SBP*
Morning DBP**
Acetylated spermidine Morning DBP**
Putrescine**
Water content*
BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
*Values at the end of the study.
**Differences between the extent of change (final values - initial values).
TENSIA subgroup analysis (n = 16) for correlations between TENSIA colonization anrange was observed among individuals at the beginning of
the study. In contrast, in the control group, there was a
trend towards lower total lactobacilli counts (p = 0.056).
The probiotic L. plantarum TENSIA was observed in
16/25 (64%) probiotic-treated subjects in varying amounts
(529.6 ± 232.5 gene copies).
Comparison of colonization with lactobacilli and L.
plantarum TENSIA, and correlation of colonization with
BMI, water content of body, arterial blood pressure, and
urinary polyamines
Spearman’s partial correlation analyses for both control
and TENSIA groups combined was applied to 36 indi-
viduals because the urine samples were missing in 4
controls. It was detected that the extents of change in
water content significantly affected the changes in BMI
(r = 570, p = 0.0014) when adjusted for sex and age
(Table 6). The data of TENSIA subgroup alone (n = 16
participants who were colonized) detected that the
higher lactobacilli counts at the end of the study were posi-
tively associated with higher BMI (r = 0.383 p = 0.0305)
and higher putrescine level (r = 0.475 p = 0.006). At the
same time, the changes in urinary putrescine and acety-
lated spermidine during the study were tightly inter-







r = −0.417 p = 0.0177
r = 0.714 p < 0.0001
r = −0.361 p = 0.0426









Start of study End of study Start of study End of study





















Figure 2 Changes in the gene copy numbers of lactobacilli in feces of probiotic and control groups. The gene copy numbers of total
lactobacilli per gram of feces were determined usingreal-time PCR assay with specific primers. The counts of total lactobacilli decreased in the
control group (n = 15, P = 0.056), not in the probiotic group (n = 25, P = 0.497). Dot plots indicate max-min, median, and 1st and 3rd quartiles.
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sociated with changes of DBP at morning measure-
ments (r = −0.417 p = 0.0445) and water content of
body (r = −0.361, p = 0.0426). After adjustment for
BMI, age, and sex, a positive association was observed
between TENSIA colonization and the extent of change
of DBP at morning (r = 0.617 p = 0.0248); a trend to-
ward lower morning SBP (r = −0.527 p = 0.0640) was
also observed.
Discussion
Implementation of a hypocaloric diet supplemented with
probiotic cheese containing L. plantarum TENSIA, in a
double-blind, randomized pilot study resulted in several
beneficial shifts of health markers in overweight and
obese subjects. First, the consumption of probiotic
cheese was associated with more efficient reduction of
BMI compared with ordinary cheese. This effect was
correlated with a significant decrease of water content
after probiotic cheese consumption, adjusted for sex and
age. Among patients who were taking BP-lowering
drugs, there was a significant association between L.
plantarum TENSIA colonization and both SBP and DBP
at the end of the study, as well as the magnitude of the
observed changes in each. In both the probiotic and
control groups, the reduction of total cholesterol and
low-density lipoprotein was observed after the consump-
tion of 50 g of cheese containing 26% fat for 3 weeks.
Significant reduction of the plasma triglyceride level was
detected only in the probiotic group.
The use of probiotics to reduce the body weight and
cholesterol and triglyceride indices of obese patients
seems challenging [27,28]. However, several clinical andexperimental studies have shown that probiotic lactoba-
cilli belonging to the genus Firmicutes did not help to
reduce BMI [29,30]. Species differences may be res-
ponsible for this finding, yet. For instance, a report
indicates that higher BMI is significantly related to
homofermentative L. acidophilus in an age- and sex-
adjusted population of healthy volunteers (29).
L. plantarum is a heterofermentative lactic acid bacter-
ium that has been found in a large range of environmen-
tal niches [31-35]. It has a proven ability to survive
gastric and intestinal transit and easily colonizes the
human intestinal tract. Functional properties of L.
plantarum TENSIA include antimicrobial activity; pro-
duction of polyamines and nitric oxide; and moderate
anti-oxidative ability [20]. Several studies by different in-
vestigators have described the beneficial effects of the
consumption of the species L. plantarum on human
physiology [31,36,37].
Although Smith et al. postulated that responsiveness
to probiotics may vary among individuals; such differ-
ences do not persist when probiotics are consumed for
longer than 9 days [38]. In our study even after 3 weeks
of consumption, the consumed strain was detectable in
only 64% of patients, and there were quite large differ-
ences in the numbers of gene copies of strain TENSIA.
This range of gene copies may have affected the total
counts of lactobacilli, the magnitude of change in BP
indices at the end of the study, and the metabolic data
tested.
Plausible mechanisms to explain the associations be-
tween health indices and dairy intake are still lacking. A
Japanese multicenter study of 87 overweight people
(BMI of 24.2 kg/m2) who consumed 200 g of fermented
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SBT2055 for 12 weeks demonstrated a 1.5% reduction in
BMI and hip circumference in the intervention group
and no reductions in the control group [28]. In the
present study, we observed a similar reduction of BMI
after just 3 weeks of consuming probiotic cheese accom-
panied with some other beneficial changes. Similar to
the findings of McNulty et al. [39], we did not observe
an increase of the total number of fecal lactobacilli.
However, in our study the presence and DNA copy
number of TENSIA were associated with BP reduction.
The shifts of lactobacilli count after probiotic interven-
tion that influenced the host metabolism might have
been detected in upper parts of intestine [29,40].
In the present pilot study, the reduction of arterial BP
was mainly achieved by BP-lowering medications; how-
ever, there was a relevant trend toward an association be-
tween the lowering of both morning SBP and DBP and
TENSIA colonization. The reduction in SBP and DBP
after 8 weeks of intervention has been shown in mildly
hypertensive subjects using Lactobacillus helveticus or
Saccharomyces cerevisiae [41,42]. During casein degrad-
ation by Lactobacillus helveticus, angiotensin I-converting
enzyme (ACE) inhibitory peptides were produced that
exerted an antihypertensive effect in vivo [43]. ACE is a
highly selective ecto-enzyme that is involved in the
regulation of peripheral BP [44]. We detected the ACE
inhibitory activity of L. plantarum TENSIA in prelimi-
nary in vitro studies (unpublished data). In addition,
some other lactobacilli, such as Lactobacillus animalis,
produce some bioactive fractions from caseins that pos-
sess ACE-inhibitory activities [45].
The mechanisms behind the arterial BP-lowering effect
of our study may include vascular relaxation, which is
also correlated with the reduction of excess reactive oxy-
gen species in vascular biology [46,47]. Our strain, L.
plantarum TENSIA, has moderate antioxidant activity
and is able to decarboxylate ornithine and produce de-
tectable putrescine in urine [20]. Large amounts of en-
dogenous and exogenous polyamines are present in the
gut lumen of healthy humans and stimulate DNA, RNA,
and protein synthesis [48,49] and the maturation of large
intestinal mucosa [50,51]. Although a strong association
between exposure to increased counts of intestinal lacto-
bacilli and increased urinary putrescine was detected in
our patients, the amount of excreted polyamines did not
change significantly at the end of the intervention.
However, the more pronounced changes of acetylated
spermidine in urine were associated with lower changes
of DBP when measured in the morning and with lower
content of water in the body. The action of polyamines,
including their hypotensive effects, appears to depend
closely on their serum concentration [52]. In addition,
the production of nitric oxide by the TENSIA strainin vitro [20] also hints at the relaxation of blood vessels;
this may be the mechanism linking consumption of
TENSIA with BP lowering.
A randomized controlled trial has demonstrated the
effects of both milk and soy proteins on lowering BP
compared with a carbohydrate-rich diet [53]. In the
present human trial, the impact of L. plantarum
TENSIA on protein catabolism was demonstrated by the
increase of urea in blood. Increased serum urea values
are usually caused by high protein diets and/or with
some starvation. It is possible that higher counts
of lactobacilli in patients consuming cheese with L.
plantarum Tensia caused the decrease of the pH of gut.
This could be accompanied with some increase of pro-
tein putrefaction and blood urea content previously de-
scribed in experimental animals and metabolic surgery
[54-56]. However, in our patients the increased urea
values were still kept in normal ranges and also no shifts
in uric acid were detected relevant for excess of protein
catabolism towards health impairment. Moreover, the
functionality of kidneys and liver was not altered by the
3 weeks treatment with hypocaloric diet and probiotic
cheese. The possibility to prevent water retention and
hypertension with the hypocaloric diet supplemented
with probiotic cheese seems worth larger clinical and
translational studies.
The important findings of this study were that the
consumption of a hypocaloric diet supplemented with
protein-rich full-fat cheese resulted in the lowering of
blood glucose levels by 18% in both study and control
groups, while no increase in total cholesterol, low-
density lipoprotein, or triglycerides were observed.
Thus, there is good potential for probiotic cheese
containing L. plantarum TENSIA to be included in a
hypocaloric diet to reduce the symptoms of metabolic
syndrome. This finding may broaden the area of non-
medication methods that can be employed to achieve
optimal arterial BP values and normalization of the BMI,
which currently includes healthy nutrition, quitting
smoking, and increasing regular physical activity.
In conclusion, the hypocaloric diet supplemented with
a probiotic cheese can help reduce BMI, arterial BP, and
the risk of metabolic syndrome in obese patients with
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